News overview

Advancedworkshop1
News
19 September 2022
Meeting researchers’ needs: Advanced workshop Preclinical tumor immune models for therapeutic discovery and validation
With more than a hundred participants covering a broad community interested in the OI field, this successful advanced workshop featured an exciting programme.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
2 2
News
16 September 2022
Highlights of the European Society of Medical Oncology Congress 2022 in Paris
Are you curious about the highlights of the European Society of Medical Oncology Congress 2022 in Paris? Oncode's Yuva Oz was there to report about all of the interesting and relevant data presented.
YuvaOz

<span>Yuva</span><span>Oz</span>

Over 17 years of experience in Molecular Biology, Yuva completed her MSc. degree at EMBL Heidelberg and conducted her PhD research on the topic of Chromatin and Biomedical Genetics at Hubrecht Institute as a Marie-Curie fellow. Interested in clinical aspects of the research, she joined to oncology specialized clinical research organization SMS-oncology, gaining experience both in clinical trial management (early phase paediatric and adult trials) and Business Development aspects. At Oncode, she is driving the industry engagement programme to enable new alliances and collaborations between Oncode and biopharma to fast-forward research and innovation. Furthermore, working closely with Oncode Investigators, she supports technology, clinical and IP assessments for efficiently translating fundamental research into clinical benefit. She is the founder and designer at Art 4 Science, a scientific visualization – graphic design company.
Un
News
8 September 2022
4.UNCAN.eu is officially launching today!
Oncode is pleased to take part in the kick-off meeting of the CSA (Coordination and Support Action) for the 4.UNCAN.eu initiative, taking place today and tomorrow in Paris. Arising from the EU’s Mission on Cancer and Europe’s Beating Cancer plan, the initiative is focused on generating a research roadmap to better UNderstand poorly understood CANcers (UNCAN).
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

1661268226974
News
26 August 2022
Vacancy: (Senior) Stakeholder Engagement Manager
Are you looking for an exciting role where you can apply your strategic and communication skills in a dynamic, fast-paced work environment? Then you are in the right place! Oncode Institute is currently looking for a Stakeholder Engagement Manager who thrives at building new and existing relations with important stakeholders.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Oncode PEP4
News
19 August 2022
(Future) researchers and patients join forces to make true impact
For the second year in a row, Oncode’s Patient Engagement Programme had the opportunity to contribute to the bachelor course ‘Eye for Impact’ for biomedical sciences students at University Medical Center Utrecht (UMCU). A unique example of how to give substance to patient engagement in basic research. Oncode researchers and patient representatives participated in a series of lectures and interactive sessions, where the students experienced first-hand how patients and researchers can partner up.
PeterThijssen
Jos Jonkers Daniel Zingg website
News
10 August 2022
Unravelling genetic mechanism behind tumor formation can improve targeted treatment
New research by the group of Jos Jonkers explains variation in treatment response to FGFR2 inhibitors and provides a way to improve targeted therapy for cancer patients. Their work highlights the importance of analyzing the functional consequences of genetic variants found in tumors.
PeterThijssen
Oncode Icons Square research strategy copy
In the spotlight
25 April 2022
Interview on Oncode-PACT: De-risking the preclinical phase
Although Dutch fundamental cancer research is among the world’s best, findings in this area rarely result in viable cancer medicines. How should this be improved? Oncode’s Managing Director Alain Kummer, Oncode Business Development expert Emil Pot and Friso Smit, business development manager of the Utrecht Science Park, reflect on this issue, with reference to the Oncode-PACT* Growth Fund proposal. They co-created this proposal with many other stakeholders.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

2
News
4 August 2022
Chemotherapy speeds up DNA-level aging
Chemotherapy is an important part of treatment for children with cancer, contributing to the recovery of more and more children. Childhood cancer survivors do sometimes experience late effects from their treatment, including a higher risk of developing a second cancer. That risk is very small, but about five to six times greater than in the ‘normal’ population. In new research, published in Cancer Discovery, the team of Oncode Investigator Ruben Van Boxtel (Princess Máxima Center) shows that accelerated DNA aging turns out to be the main cause of the harmful effect of chemotherapy treatment.
PeterThijssen
Moesin Vermeulen
News
4 August 2022
Paving the way for targeted therapy development for peritoneal metastases in colorectal cancer
Many patients with colorectal cancer suffer from metastases in the abdominal cavity, which have a big impact on quality of life and lead to poor survival. The team of Oncode Investigator Louis Vermeulen and collaborators have now shown that peritoneal metastases occur almost exclusively in a particular type of colon cancer: CMS4. With their research, published in Nature Communications, the team is now able to explain why and how this type of colon cancer can metastasize to the peritoneum.
PeterThijssen
Un
News
29 July 2022
A new European strategic initiative to better understand cancer: 4.UNCAN.eu is calling for experts!
4.UNCAN.eu is launching a “Call for Expert Working Groups” (EWGs). Scientific leaders with expertise in 6 different areas of cancer research will be invited to help identify the research priorities that need to be addressed to reach a new level of understanding in cancer. These research priorities are intended to serve as guidelines for the European Scientific Community (including the Cancer Mission Board) to set specific calls for funding, as well as use cases to feed a European Federated Cancer Research Data Hub.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Oncode icons square 01
News
27 July 2022
Oncode Investigator Madelon Maurice receives KWF funding for innovative SureTAC technology
At the start of the year, Argobio and Oncode have teamed up with Oncode Investigator Madelon Maurice (UMCU) and launched Laigo Bio, a new spin-off from the University Medical Center Utrecht (UMCU) in the emerging field of targeted protein degradation. Now, KWF has announced that this public-private collaboration will receive 1.2 million euros subsidy from the PPP allowance that Health~Holland makes available to KWF from the top sector Life Sciences & Health (LSH).
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>